An updated expert consensus on childhood nocturnal enuresis (NE) provides a comprehensive framework for diagnosis and management, aiming to improve outcomes through earlier intervention and personalized treatment. The new guidance, published in the World Journal of Pediatrics, includes 18 recommendations covering classification, evaluation, first-line therapy, and referral pathways.
The consensus, developed by researchers from the Children's Hospital of Fudan University and the Chinese Cooperative Group for the Management of Pediatric NE, updates the previous 2014 guidelines. It lowers the diagnostic threshold for NE to at least one involuntary nighttime void per month for three months in children aged five years or older, a shift from the previous weekly standard. This change enables earlier identification and treatment, potentially reducing the psychological and social impact of bed-wetting.
Central to the new framework is the distinction between monosymptomatic NE (MNE), where no daytime lower urinary tract symptoms are present, and non-monosymptomatic NE (NMNE), which includes daytime symptoms such as urgency or incontinence. This classification drives treatment decisions, with phenotype-driven first-line therapy for MNE: desmopressin for nocturnal polyuria and enuresis alarm for reduced bladder capacity, and combination therapy for mixed types. For NMNE, management prioritizes daytime symptoms and comorbidities, especially constipation, which affects 36-80% of these children.
The voiding diary is now a cornerstone of diagnosis, requiring at least two daytime charts and seven consecutive nights of fluid intake and voids. This allows clinicians to phenotype children and tailor treatment accordingly. The consensus also outlines clear referral criteria: primary care can manage MNE, but non-responders or suspected NMNE require specialist evaluation with urodynamics and lumbosacral MRI. For refractory cases, defined as less than 50% improvement after three months, systematic re-evaluation of adherence, diary findings, and underlying causes is advised before escalating treatment.
The authors emphasize that NE should not be treated as a single disorder. The updated pathway encourages clinicians to identify the child's specific pattern, look for daytime symptoms and comorbidities, and match treatment to the likely underlying mechanism while involving the family. They stress that apparent treatment failure should prompt a careful review before adding stronger therapy.
In practice, these recommendations could help pediatricians and primary-care clinicians identify children who can be managed locally versus those needing specialist care. Clearer use of voiding diaries and symptom-based classification may reduce trial-and-error treatment, while early attention to constipation, sleep-disordered breathing, ADHD, and daytime urinary symptoms could improve response rates. The framework also supports timely referral and better coordination across care levels.
The authors acknowledge that some recommendations reflect Chinese practice patterns and that evidence remains limited for areas such as desmopressin withdrawal. Future trials and multidisciplinary care models could further refine individualized treatment. The full consensus is available at https://doi.org/10.1007/s12519-026-01051-4.
